Fucicort

Selected form

Method of action: Antibacterial Local, Corticosteroids, Dermatological Preparations, Glucocorticoid

Treatment option: Atopic Dermatitis, Dermatitis, Discoid Eczema, Infection, Infection,Bacterial, Eczema

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fucicort

Quick Facts

Property	Description
Active Ingredients	Fusidic Acid and Betamethasone Valerate
Form	Cream or Ointment
Pharmacological Class	Topical Corticosteroid and Antibiotic Combination
Common Use	Managing inflamed skin with associated bacterial presence
Origin	Semi-synthetic/Synthetic

Fucicort is formally classified as a fixed-dose combination product designed for localized topical application, belonging to the pharmacological group of corticosteroids and antibiotics in combination, for external use. This preparation is formulated to address skin conditions where there is both significant inflammation and the presence of bacterial involvement.

The product's identity is defined by its two active ingredients: the antibiotic Fusidic Acid and the corticosteroid Betamethasone Valerate. Fusidic Acid is highly effective against specific Gram-positive organisms, most notably Staphylococcus aureus. Betamethasone Valerate is a synthetic glucocorticoid known for its potent anti-inflammatory properties.

This specific combination of Fusidic Acid and the Valerate ester of Betamethasone distinguishes Fucicort, offering a reliable anti-infective action alongside a potent anti-inflammatory effect. The general therapeutic purpose is the concurrent management of symptoms and bacterial presence in inflammatory skin disorders, which is clinically recognized for effectively managing symptoms where single-agent therapies may be insufficient.

Its dual action is intended to provide comprehensive relief by delivering both the anti-infective agent and the potent anti-inflammatory agent simultaneously. This combination allows the preparation to efficiently address the symptoms of swelling, redness, and persistent itching while promoting the healing of the affected skin area.

Regulatory References

Fucicort Cream New Zealand Data Sheet

What side effects are possible with Fucicort?

Possible Side Effects and Safety Information

The safety profile for Fucicort is primarily characterized by local application site reactions and the known class effects of potent topical corticosteroids, based on regulatory documentation. The majority of reported adverse events are localized and non-serious.

Frequency-Classified Adverse Reactions

Side effects are classified by their documented frequency. Common reactions (affecting 1 in 100 to 1 in 10 people) typically involve the application site, including pruritus (itching), a burning sensation, or irritation. Uncommon reactions (affecting 1 in 1,000 to 1 in 100 people) can include hypersensitivity, contact dermatitis, aggravation of existing eczema, or application site pain. Rare reactions are also documented, and in some regulatory texts, blurred vision and withdrawal reactions (after stopping prolonged treatment) are listed with a not known frequency.

Systemic and Exposure-Related Safety

Adverse effects are grouped by the affected organ system, including Skin and Subcutaneous Tissue Disorders (e.g., skin thinning, striae, telangiectasia) and potential effects on Eye Disorders (e.g., glaucoma, cataract) and the Endocrine System (e.g., adrenocortical suppression). These serious reactions are associated with the corticosteroid component, particularly when the medicine is used prolonged or continuously, on large surface areas, or under occlusion. The pediatric population is explicitly noted as more susceptible to systemic effects, such as adrenal suppression, due to their higher ratio of skin surface area to body weight. Furthermore, regulatory texts note that long-term use may increase the risk of bacterial resistance to fusidic acid.

Safety-Related Constraints

Application near the eyes should be avoided due to the documented risk of raised intra-ocular pressure. The potential of the corticosteroid to mask, aggravate, or activate latent infections is also noted in official safety information.

Overdose and Emergency Response

Overdose and when to seek help: Official Regulatory Information for Fucicort

The officially documented risk of overdose with Fucicort relates primarily to the systemic absorption of the potent corticosteroid component, Betamethasone Valerate, following prolonged, excessive topical use, application over large surface areas, or use under occlusion. Acute oral ingestion of the contents of a tube is generally considered by regulators to be unlikely to cause significant clinical problems.

Documented Overdose Manifestations

Manifestation	Regulatory Context
Systemic Absorption	Leads to Hypothalamic-Pituitary-Adrenal (HPA) axis suppression and features of Cushing's syndrome (hypercortisolism).
Glucocorticosteroid Insufficiency	A severe outcome risked upon abrupt cessation of the product after chronic misuse.
Pediatric Susceptibility	Children are at greater risk of HPA axis suppression, potentially exhibiting linear growth retardation, delayed weight gain, or signs of intracranial hypertension.

Emergency Response and Required Actions

Individuals must seek immediate medical attention following any accidental ingestion or if systemic symptoms of hypercortisolism or HPA axis suppression are suspected.
The mandated management involves gradual withdrawal of the product, typically by reducing the frequency of application or substituting a less potent corticosteroid.
Treatment is symptomatic and supportive, requiring periodic evaluation for HPA axis suppression under medical supervision.
No specific antidote is known for the systemic effects resulting from overdose.

Therapeutic Uses of Fucicort

What Fucicort Treats: Main Uses and Benefits

Fucicort is commonly used in therapeutic areas involving heightened skin responses and associated microbial presence. The cream is generally indicated for eczematous dermatoses when secondary bacterial infection is confirmed or suspected.

It is relevant in conditions characterized by periods of heightened symptoms, such as Atopic Dermatitis, Contact Dermatitis, Lichen Simplex Chronicus, and certain presentations of Psoriasis. The medication helps address symptom clusters that may become intense or disruptive, specifically severe itching (pruritus), noticeable redness, and related swelling of lesions. Applied during phases of increased distress, the cream provides support that helps ease the overall symptom burden, and provides supportive relief when symptoms interfere with routine activities.

Quick Fact: Relief for Complicated Dermatoses
Primary Focus: Used in conditions involving inflammatory and irritative processes when a bacterial element is present.
Symptom Focus: Helps address symptoms of physical discomfort, including itching, redness, and swelling.

Eligibility and Restrictions for Use

Who can and cannot use Fucicort? — Official Regulatory Information

Fucicort (fusidic acid and betamethasone) is authorized for use in individuals with inflammatory skin conditions, such as eczema or dermatitis, that are suspected or confirmed to have a bacterial infection.

Contraindications (Must Not Use)

Official regulatory documents state that this medicine is contraindicated for patients with:

Known allergy or hypersensitivity to fusidic acid, betamethasone valerate, or any of its inactive ingredients.
Systemic fungal infections.
Primary skin infections caused by fungi, viruses (e.g., herpes, chickenpox), or bacteria that are untreated or uncontrolled.
Skin manifestations related to tuberculosis or syphilis that are untreated.
Specific skin disorders, including perioral dermatitis and rosacea.

Use in Special Populations

Children: Use requires special caution due to the risk of systemic effects from the corticosteroid component. Prolonged use, large amounts, and occlusive dressings should be avoided. The medicine is contraindicated for infected dermatitis in infants under one year of age in some jurisdictions.
Pregnancy and Lactation: Use during pregnancy is generally advised against unless clearly necessary. If breastfeeding, it is recommended to avoid applying the cream to the breast to prevent infant ingestion.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Fucicort (Fusidic Acid and Betamethasone Valerate combination) is structured around its topical route of administration.

Interactions with systemically administered medicinal products are formally classified as minimal in regulatory documents. This classification is based on the negligible systemic exposure that occurs following the recommended use of the cream or ointment.

Consequently, the regulatory labeling does not contain specific documentation regarding drug–drug interactions typically found with oral medicines. No official interaction studies have been performed for this topical combination product.

Official Regulatory Findings

Category	Official Documented Information
Specific Interacting Medicines	None are explicitly listed in the regulatory interaction section.
Timing-Based Rules	None documented; no mandatory separation requirements for co-administered products are required.
Metabolic Interactions	None documented; no specific enzyme-mediated interactions are listed.
Contraindicated Combinations	None formally documented as contraindicated due to systemic interaction risk.

The overall official interaction structure is defined by the absence of specific interaction data and the conclusion that systemic interaction risk is minimal. This profile confirms that the regulatory label does not specify interactions with food, alcohol, or herbal products.

Mechanism of Action

The pharmacological action of Fucicort relies on the synergistic mechanisms of its two active components, betamethasone and fusidic acid. Betamethasone, a potent synthetic glucocorticoid, functions as an agonist for the intracellular glucocorticoid receptor (GR). Upon ligand binding, the activated GR-complex translocates to the nucleus to modulate gene transcription. This action specifically downregulates the expression of genes encoding pro-inflammatory mediators, including cytokines and chemokines, while simultaneously inducing the synthesis of anti-inflammatory proteins such as lipocortin (Annexin A1). The lipocortin protein inhibits phospholipase A2 activity, preventing the liberation of arachidonic acid and subsequent generation of eicosanoids. Fusidic acid, an antibacterial agent, acts by inhibiting bacterial protein synthesis. It selectively binds to the elongation factor G (EF-G) complex on the bacterial ribosome, specifically interfering with the translocation of the peptidyl-tRNA during the translation process. This interference arrests the extension of the polypeptide chain, resulting in the cessation of cellular growth.

Dosage and Administration Information

How to Use Fucicort: Official Administration Guidelines

Fucicort (Fusidic Acid and Betamethasone Valerate) is designed strictly for cutaneous use and is applied topically to the skin. The official usage protocol defines precise constraints for administration, frequency, and duration.

Application Regimen and Limits

Instruction Domain	Official Requirement
Route of Administration	Strictly topical (dermal) use only.
Dosing Schedule	Apply a small amount or thin layer gently onto the affected area of skin.
Frequency	Application is typically prescribed as twice daily, usually once in the morning and once in the evening.
Course Duration	A single continuous treatment course must not exceed 14 days (two weeks).

Procedural and Population-Specific Constraints

The standard procedure involves washing hands before and after application (unless the hands are the area being treated). The product must be applied only to the localized area of concern. Application should be avoided near the eyes or for prolonged periods on the face.

For infants and children (over 1 year of age), special care is required; continuous long-term topical therapy is to be avoided, and use on large body surfaces or under occlusion (such as tight nappies) is generally constrained. If a dose is missed, instructions recommend applying the missed dose as soon as possible and then reverting to the regular twice-daily schedule; a double dose should not be applied to compensate.

Recent Clinical Evidence

Overview of Clinical Research

Fucicort, a combination product containing fusidic acid (an antibiotic) and betamethasone valerate (a corticosteroid), is studied primarily for the short-term topical treatment of inflammatory skin conditions, such as eczema or dermatitis, where a bacterial infection is present or suspected. Clinical research focuses on evaluating the combination's effect on both the inflammatory and infectious components of the condition.

Studies in Infected Atopic Dermatitis

Clinical trials have examined the use of Fucicort in patients with clinically infected atopic dermatitis (eczema). In randomized studies comparing the combination treatment to corticosteroids alone, research has shown that combining the antibiotic fusidic acid with a corticosteroid may lead to a greater reduction in both the severity of eczematous lesions and the level of bacterial colonization compared to the steroid applied alone. These studies typically assess outcomes within a short treatment period, such as two weeks.

Formulation and Safety Research

Recent research has also explored new formulations of the product, such as a lipid cream version, to compare its performance against the established cream formulation. One large, randomized study involving hundreds of patients with infected atopic dermatitis observed that the clinical and anti-bacterial effects of the newer lipid cream formulation were similar to those of the established Fucicort cream formulation.

Safety evaluations in clinical trials commonly monitor local skin reactions, such as irritation or burning, and systemic effects associated with topical corticosteroids, including the potential for adrenal suppression or skin atrophy with prolonged use. Research indicates that limiting the treatment duration minimizes the risk of these side effects and also addresses concerns regarding the development of antibiotic resistance to fusidic acid.

Frequently Asked Questions (FAQ)

Common questions about Fucicort (FAQ)

Q: How quickly does Fucicort start to work?

Official product information describes the betamethasone component as a topical corticosteroid that is rapidly effective in managing responsive inflammatory skin conditions. This rapid anti-inflammatory action may lead to a quick reduction in swelling and redness.

Q: Is it necessary to finish the whole tube of Fucicort even if the skin clears up?

Official guidance generally states that the full treatment course is recommended, even if the skin appears clearer before the course is finished. Completing the full course as prescribed may reduce the risk of the infection returning or becoming resistant to the antibiotic component.

Q: What is the difference between Fucicort and Fucidin H?

Fucicort and Fucidin H are both combination creams, but they contain different corticosteroids (steroids). Fucicort contains betamethasone, which is classified as a potent steroid. In contrast, Fucidin H contains hydrocortisone, which is a milder steroid.

Q: What is the difference between Fucicort and similar combination creams?

Fucicort is defined by its fixed combination of the antibiotic fusidic acid and the potent corticosteroid betamethasone valerate. This specific dual formulation distinguishes it from other combination creams, which may use different antibiotics or steroids.

Q: Is Fucicort the same medication as Fucibet?

Yes, Fucicort and Fucibet are different brand names for the same fixed combination product: fusidic acid and betamethasone valerate. The specific name used is dependent on the country or region where the medicine is marketed.

Q: Does Fucicort cream contain any ingredients that might cause an allergic reaction?

Yes, official product documents list excipients (inactive ingredients) such as methyl and propyl hydroxybenzoate, cetostearyl alcohol, and potassium sorbate. The medicine is formally contraindicated (must not be used) if a patient has a known allergy to any of its ingredients.

Q: Is Fucicort available without a prescription?

No. Fucicort (fusidic acid and betamethasone) is classified by regulatory authorities as a Prescription Only Medicine (POM) or Control Medicine in most regions where it is available. This means it requires a valid prescription for dispensing.

Q: Is Fucicort used for conditions other than eczema?

Official indications state that Fucicort is used for inflammatory skin conditions like eczema and dermatitis where a bacterial infection is confirmed or suspected. These terms cover a broad group of skin inflammation conditions.

Q: Can Fucicort be used on the face?

Regulatory documents advise avoiding application near the eyes and avoiding prolonged periods of use on the face. This is due to the increased risk of certain side effects like skin thinning and eye issues in those sensitive areas.

Q: Can Fucicort be used on open wounds or broken skin?

The product is indicated for dermatitis, but official information often advises against using topical steroids on skin areas that have cuts, scrapes, or burns unless specifically directed. The constraints are based on studies involving intact affected skin.

Q: Is Fucicort effective against all types of bacterial skin infections?

No. Official documents state that the antibiotic component, fusidic acid, is primarily effective against Gram-positive bacteria, such as Staphylococcus aureus. Its activity does not extend to all types of bacterial skin infections.

Q: Can Fucicort be used for treating boils or carbuncles?

Fucicort is indicated for inflammatory dermatoses (inflamed skin conditions). It is not listed as the primary treatment for deep, localized infections like boils or carbuncles. The management of such infections often involves systemic treatment.

Q: Is Fucicort safe for use on areas of thin skin like the armpits or groin?

Regulatory warnings indicate that use under occlusion (such as tight dressings) or on thin skin areas must be done with special caution. This constraint is necessary because using the product in this manner increases systemic absorption and the potential risk of side effects.

Q: Does Fucicort have any effect on acne?

Fucicort is not indicated for the treatment of acne. Furthermore, its potent steroid component (betamethasone) is listed as contraindicated (not to be used) for the related skin condition rosacea.

Q: What happens if I stop using Fucicort suddenly?

Long-term or prolonged use of potent topical steroids is associated with the potential risk of rebound flares after treatment cessation, a condition sometimes called Topical Steroid Withdrawal (TSW). These reactions can involve intense redness, stinging, and burning sensations.

Q: What is the difference in strength between Fucicort and other common steroid creams?

Fucicort contains Betamethasone Valerate, which is officially classified by regulatory bodies as a potent corticosteroid (often classified as Group III). This category reflects its relative strength compared to milder or weaker topical steroids.

Q: How does Fucicort's safety profile compare to other high-strength topical steroids?

The safety profile for Fucicort is defined by the known class effects of potent topical corticosteroids. These effects include potential risks like skin thinning (atrophy) and HPA axis suppression (affecting hormone balance) when the product is used improperly (e.g., for too long or on large areas).

Q: What research indicates about Fucicort use in older patients?

Regulatory documents indicate that the observed safety and efficacy profile for Fucicort in older patients (aged 65 years and older) is considered similar to that in younger adults when used as directed for the approved duration.

How should Fucicort be stored and disposed of?

How to Store and Dispose of Fucicort?

Regulatory documents define strict rules for the storage and disposal of Fucicort cream.

Storage Conditions

Fucicort must be stored at a temperature not exceeding 25 C or 30 C and must not be refrigerated or frozen. The product should be kept in its original container and must always be stored out of the sight and reach of children.

Stability and Disposal

The cream has a limited stability period once the tube is first opened, and any unused portion must be discarded after 3 to 6 months as specified on the label. Expired or unused medicine must not be disposed of in household waste or wastewater. Disposal must be carried out in accordance with local pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.